A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Conditions: Gout Interventions: Biological: Pegloticase; Drug: Methotrexate Sponsors: Horizon Therapeutics Ireland DAC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials